Synergistic effects of ginsenoside Rg3 and cyclophosphamine on tumor growth and angiogenesis in lung cancer

African Journal of Biotechnology

Volumn 10, Issue 49, 2011, Pages 10040-10044

  Hang, Li ^a   Jun, Wang ^b   Yanfeng, Guan ^c   Wenjun, Yang ^a   Aiying, Aiying Suo ^a   Meihua, Chu ^a   Chenyu, Wang ^a   Jing, Jiang ^a   Shengping, Zhai ^a   Qishan, Mao ^a  

^a YANTAI YUHUANGDING HOSPITAL   (China)

^b Laizhou People's Hospital   (China)

^c Department of Gastroenterology   (China)

Author keywords

Angiogenesis; Cyclophosphamide; Ginseng; Lung cancer

Indexed keywords

CYCLINE; CYCLOPHOSPHAMIDE; GINSENOSIDE RG 3; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; LUNG CANCER; MICROVASCULATURE; MICROVESSEL DENSITY; MONOTHERAPY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; QUALITY OF LIFE; SURVIVAL TIME; TUMOR VASCULARIZATION;

MUS; PANAX GINSENG;

EID: 80052486836     PISSN: 16845315     EISSN: None     Source Type: Journal    
DOI: 10.5897/ajb11.829     Document Type: Article

References (20)

1. Bello L, Carrabba G, Giussani C, Lucini V, Cerutti F, Scaglione F (2001). Low dose chemotherapy combined with an antiangiogenic drug reduces human glioma growth in vivo. Cancer Res., 61(20): 7501-7506.
2. Chen MW, Ni L, Zhao XG, Niu XY (2005). The inhibition of 20(R)- ginsenoside Rg3 on the expressions of angiogenesis factors proteins in human lung adenocarcinoma cell line A549 and HUVEC304 cell (Chin). Chin. J. Chin. Materia Medica, 30(5): 357-360.
3. Davis K, Yount S, Wagner L, Cella D (2004). Measurement and management of health-related quality of life in lung cancer. Clin. Adv. Hematol. Oncol., 2(8): 533-40.
4. Ellis LM, Liu W, Ahmad SA, Fan F, Jung YD, Shaheen RM (2001). Overview of angiogenesis: biologic implications for antiangiogenic therapy. Semin Oncol. 28(5): 94-104.
5. Hanahan D, Bergers G, Bergsland E (2000). Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J. Clin. Invest., 105(8): 1045-1047.
6. Isozaki H, Okajima K, Ichinona T (1996). Significance of proliferating cell nuclear antigen (PCNA) expression in gastric cancer in relation to lymph node metastasis. J. Surg. Oncol., 61(2): 106-110.
7. Keum YS, Han SS, Chun KS, Park KK, Park JH, Lee SK (2003). Inhibitory effects of the ginsenoside Rg3 on phorbol ester-induced cyclooxygenase-2 expression, NF-kappaB activation and tumor promotion. Mutat. Res., 523-524: 75-85.
8. Kim HS, Lee EH, Ko SR, Choi KJ, Park JH (2004). Effects of ginsenosides Rg3 and Rh2 on the proliferation of prostate cancer cells. Arch. Pharm. Res., 27(4): 429-435.
9. Klement G, Baruchel S, Rak J, Man S, Clark K, Hicklin DJ (2000). Continuous low dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J. Clin. Invest., 105(8): 1-17.
10. Iishi H, Tatsuta M, Baba M, Uehara H, Nakaizumi A, Shinkai K (1997). Inhibition by ginsenoside Rg3 of bombesin-enhanced peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane in Wistar rats. Clin. Exp. Metastasis, 15(6): 603-611.
11. Lee SY, Kim GT, Roh SH, Song JS, Kim HJ, Hong SS (2009). Proteomic analysis of the anti-cancer effect of 20S-ginsenoside Rg3 in human colon cancer cell lines. Biosci Biotechnol Biochem. 73(4): 811-816.
12. Liu Jw, Chen JX, Yu LH, Tian YX, Cui XY, Yan Q (2004). Inhibitory effect of ginsenoside-Rg3 on lung metastasis of mouse melanoma transfected with ribonuclease inhibitor (Chin). Chin. J. Oncol., 26(12): 722-725.
13. Maria RR, Francesca C, Francesca G (2005). Microdensity vessels and with vascular endothelial growth factor expression in ovarian carcinoma. Int. J. Surg. Pathol., 13(87): 135-142.
14. Mochizuki M, Yoo YC, Matsuzawa K, Sato K, Saili I, Tonooka S (1995). Inhibitory effect of tumor metastasis in mice by saponin, ginsenoside-Rb2, 20(R)-and 20(S)-ginsenoside-Rg3, of red ginsen. gBiol. Pharm. Bull., 18(5): 1197-202.
15. Morioka H, Weissbach L, Vogel T, Petur NG, Faircloth GT, Shao L (2003). Antiangiogenesis treatment combined with chemotherapy produces chondrosarcoma necrosis. Cancer Res. 9(3): 1211-17.
16. Nguyen JT, Wu P, Clouse ME, Hlatky L, Terwillinger EF (1998). Adenoassociated virus-mediated delivery of antiangiogenic factors as an antitumor strategy. Cancer Res. 58(24): 5673-5677.
17. Niu YJ, Liu FL, Zhou ZY, Wang HY (2002). Expression of CD44V6 and PCNA in squamous cell carcinomas. Chin. Med. J., 115(10): 1564-1568.
18. Overmoyer B, Fu P, Hoppel C, Radivoyevitch T, Shenk R, Persons M (2007). Inflammatory breast cancer as a model disease to study tumor angiogenesis: results of a phase IB trial of combination SU5416 and doxorubicin. Clin. Cancer Res., 13(19): 5862-5868.
19. Yue PY, Wong DY, Wu PK, Leung PY, Mak NK, Yeung HW (2006). The angiosuppressive effects of 20(R)-ginsenoside Rg3. Biochem. Pharmacol., 72(4): 437-445.
20. Zhang Q, Kang X, Yang B, Wang J, Yang F (2008). Antiangiogenic effect of capecitabine combined with ginsenoside Rg3 on breast cancer in mice. Cancer Biother Radiopharm. 23(5): 647-653.